See more : Affordable Robotic & Automatio (AFFORDABLE.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Corvus Pharmaceuticals, Inc. (CRVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Corvus Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Stolt-Nielsen Limited (0OHK.L) Income Statement Analysis – Financial Results
- Aton Resources Inc. (AAN.V) Income Statement Analysis – Financial Results
- St-Georges Eco-Mining Corp. (SX.CN) Income Statement Analysis – Financial Results
- Rosslyn Data Technologies plc (RDT.L) Income Statement Analysis – Financial Results
- Macondray Capital Acquisition Corp. I (DRAYU) Income Statement Analysis – Financial Results
Corvus Pharmaceuticals, Inc. (CRVS)
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 151.00K | 367.00K | 460.00K | 632.00K | 743.00K | 847.00K | 842.00K | 594.00K | 148.00K | 0.00 |
| Gross Profit | -151.00K | -367.00K | -460.00K | -632.00K | -743.00K | -847.00K | -842.00K | -594.00K | -148.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.53M | 24.47M | 29.12M | 31.83M | 37.98M | 38.59M | 46.31M | 29.36M | 11.35M | 41.46K |
| General & Administrative | 6.88M | 8.10M | 9.52M | 11.93M | 10.88M | 10.64M | 10.22M | 7.62M | 2.42M | 134.18K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.88M | 8.10M | 9.52M | 11.93M | 10.88M | 10.64M | 10.22M | 7.62M | 2.42M | 134.18K |
| Other Expenses | 0.00 | 587.00K | 235.00K | 37.46M | 0.00 | 0.00 | 0.00 | 0.00 | -17.60M | 0.00 |
| Operating Expenses | 23.41M | 32.57M | 38.63M | 43.76M | 48.85M | 49.22M | 56.52M | 36.98M | 13.77M | 175.64K |
| Cost & Expenses | 23.41M | 32.57M | 38.63M | 43.76M | 48.85M | 49.22M | 56.52M | 36.98M | 13.77M | 175.64K |
| Interest Income | 0.00 | 654.00 | 0.00 | 540.00K | 2.18M | 2.28M | 861.00K | 601.00K | 35.00K | 0.00 |
| Interest Expense | 1.58M | 654.00K | 15.00K | 540.00K | 2.18M | 2.28M | 0.00 | 601.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 151.00K | 367.00K | 460.00K | 632.00K | 743.00K | 847.00K | 842.00K | 594.00K | 148.00K | 175.64K |
| EBITDA | -26.88M | -40.94M | -42.78M | -5.36M | -48.85M | -46.09M | -54.82M | -35.78M | -31.19M | 14.64K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -23.41M | -32.57M | -38.63M | -43.76M | -48.85M | -49.22M | -56.52M | -36.98M | -13.77M | -175.64K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -3.62M | -8.74M | -4.61M | 37.77M | 2.18M | 2.28M | 861.00K | 601.00K | -17.57M | 0.00 |
| Income Before Tax | -27.03M | -41.31M | -43.24M | -6.00M | -46.67M | -46.94M | -55.66M | -36.38M | -31.34M | -175.64K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 8.74M | -5.04M | -1.17M | -2.93M | 2.28M | -842.00K | -594.00K | -35.00K | 0.00 |
| Net Income | -27.03M | -50.05M | -38.20M | -4.82M | -43.75M | -46.94M | -55.66M | -36.38M | -31.34M | -175.64K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.56 | -1.08 | -0.91 | -0.16 | -1.49 | -1.71 | -2.72 | -2.36 | -1.54 | -1.03 |
| EPS Diluted | -0.56 | -1.08 | -0.91 | -0.16 | -1.49 | -1.71 | -2.72 | -2.36 | -1.54 | -1.03 |
| Weighted Avg Shares Out | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M | 27.51M | 20.49M | 15.42M | 20.41M | 170.00K |
| Weighted Avg Shares Out (Dil) | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M | 27.51M | 20.49M | 15.42M | 20.41M | 170.28K |
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2023 Earnings Call Transcript
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
3 Hot Penny Stocks To Watch Before Next Week
Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
3 High-Potential Penny Stocks to Buy Now
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
Source: https://incomestatements.info
Category: Stock Reports